Phase 1b: Multiple Ascending Dose Study (NCT03014609) Study Title: "Safety, Tolerability, PK and PD of Multiple Doses of Cagrilintide in Subjects With Type 2 Diabetes" Status: Completed Phase: Phase 1b Enrollment: 56 participants with T2D Study Period: 2017-2018 Design: Randomized, double-blind, placebo-controlled Duration: 12 weeks Dose Range: 0.3-4.5 mg SC weekly Population: T2D, BMI 25-40, HbA1c 7-10% Key Results: Weight Loss: 6.0 kg (4.5 mg dose) vs
Two such protomers are linked by multiple disulfide bonds, forming a stable, covalent dimer (Supplementary Fig
Az emberi szervezetben a mjban, az agyban, valamint a vesben szintetizldik
Our data delineate the therapeutic superiority of the di-agonist, GLP1/E, in the management of the metabolic alterations of PCOS, with beneficial effects also on ovarian function in our PCOS model of preserved ovulatory function